University of Iowa Pharmaceuticals (UI Pharmaceuticals), a division of the University of Iowa College of Pharmacy, supported Lixte Biotechnology Holdings, Inc. in by manufacturing clinical drug supplies of Lixte’s investigational drug LB-100. Lixte has just announced that the first two patients have enrolled in a National Cancer Institute (NCI) trial of the ability of LB-100 to enter recurrent malignant brain tumors. This study is being conducted by NCI under a Cooperative Research and Development Agreement (CRADA) with Lixte. Dr. John S. Kovach, CEO of Lixte, said, “Primary malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug, temozolomide has been the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme, GBM) for decades with some further benefit gained by the addition of one or more anti-cancer drugs but without major advances in overall survival for the majority of patients. In animal models of GBM, Lixte’s novel protein phosphatase inhibitor, LB-100, enhances the effectiveness of both radiation, temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment in the clinic.” UI Pharmaceuticals is proud to have been able to support this study with investigational drug supply. For more information go to:
Monday, February 17, 2020